RUNX1-Regulated Signaling Pathways in Ovarian Cancer

Ovarian cancer is the leading cause of gynecological death worldwide, and its poor prognosis and high mortality seriously affect the life of ovarian cancer patients. Runt-related transcription factor 1 (RUNX1) has been widely studied in hematological diseases and plays an important role in the occur...

Full description

Saved in:
Bibliographic Details
Published inBiomedicines Vol. 11; no. 9; p. 2357
Main Authors Chen, Yuanzhi, He, Yingying, Liu, Shubai
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 23.08.2023
MDPI
Subjects
Apoptosis
Cancer therapies
Cell growth
Chemotherapy
clinical therapeutic target
Development and progression
Genes
Health aspects
Hematological diseases
Hematology
Leukemia
Medical research
Medicine, Experimental
Metastases
Mortality
Ovarian cancer
Patients
Phosphorylation
Prognosis
Proteins
Review
Runt-related transcription factor 1 (RUNX1)
Runx1 protein
Signal transduction
signaling pathways
Solid tumors
Transcription factors
Tumors
Online AccessGet full text

Cover

More Information
Summary:Ovarian cancer is the leading cause of gynecological death worldwide, and its poor prognosis and high mortality seriously affect the life of ovarian cancer patients. Runt-related transcription factor 1 (RUNX1) has been widely studied in hematological diseases and plays an important role in the occurrence and development of hematological diseases. In recent years, studies have reported the roles of RUNX1 in solid tumors, including the significantly increased expression of RUNX1 in ovarian cancer. In ovarian cancer, the dysregulation of the RUNX1 signaling pathway has been implicated in tumor progression, metastasis, and response to therapy. At the same time, the decreased expression of RUNX1 in ovarian cancer can significantly improve the sensitivity of clinical chemotherapy and provide theoretical support for the subsequent diagnosis and treatment target of ovarian cancer, providing prognosis and treatment options to patients with ovarian cancer. However, the role of RUNX1 in ovarian cancer remains unclear. Therefore, this article reviews the relationship between RUNX1 and the occurrence and development of ovarian cancer, as well as the closely regulated signaling pathways, to provide some inspiration and theoretical support for future research on RUNX1 in ovarian cancer and other diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11092357